{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:46Z","timestamp":1782337246908,"version":"3.54.5"},"reference-count":11,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY21H290003"],"award-info":[{"award-number":["LY21H290003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81503296"],"award-info":[{"award-number":["81503296"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35847","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T12:11:47Z","timestamp":1723291907000},"page":"e35847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory\/relapsed AML: Case report and exploration of possible mechanisms"],"prefix":"10.1016","volume":"10","author":[{"given":"Man","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaonan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonglin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyin","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-9365","authenticated-orcid":false,"given":"Dijiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e35847_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e35847_bib2","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s00018-008-8637-6","article-title":"Mcl-1 is a potential therapeutic target in multiple types of cancer","volume":"66","author":"Akgul","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.heliyon.2024.e35847_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/gcc.20830","article-title":"Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML","volume":"50","author":"R\u00fccker","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.heliyon.2024.e35847_bib4","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1134\/S0006297910130092","article-title":"Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition","volume":"75","author":"Rulina","year":"2010","journal-title":"Biochemistry (Mosc)."},{"key":"10.1016\/j.heliyon.2024.e35847_bib5","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3892\/or.2013.2328","article-title":"Core binding factor acute myeloid leukaemia and c-KIT mutations","volume":"29","author":"Riera","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e35847_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.heliyon.2024.e35847_bib7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/mc.23600","article-title":"Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients","volume":"62","author":"Zong","year":"2023","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.heliyon.2024.e35847_bib8","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283606","article-title":"Prognostic value of European Leukemia Net 2022 criteria and genomic clusters using machine learning in older adults with acute myeloid leukemia","author":"Park","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e35847_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e35847_bib10","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e35847_bib11","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.heliyon.2025.e42725","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000}}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024118786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024118786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:55:50Z","timestamp":1773183350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024118786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":11,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024118786"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35847","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gilteritinib overcomes primary resistance to venetoclax in a patient with FLT3 wild-type refractory\/relapsed AML: Case report and exploration of possible mechanisms","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35847","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35847"}}